Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Alzamend Neuro, Inc. - Common Stock
(NQ:
ALZN
)
2.050
+0.150 (+7.90%)
Streaming Delayed Price
Updated: 1:21 PM EST, Jan 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alzamend Neuro, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants
↗
November 19, 2025
Alzamend Neuro completed its first Phase 2 trial for AL001, a novel lithium therapy aiming for better brain delivery and safety, reducing the need for drug monitoring.
Via
Benzinga
Hewlett Packard Enterprise To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
↗
August 21, 2025
Via
Benzinga
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium
July 28, 2025
From
Alzamend Neuro, Inc.
Via
GlobeNewswire
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs
July 23, 2025
From
Alzamend Neuro, Inc.
Via
GlobeNewswire
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule
June 16, 2025
Capital Raised to Support Five Clinical Trials
From
Alzamend Neuro, Inc.
Via
GlobeNewswire
Which stocks are experiencing notable movement on Friday?
↗
May 30, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
↗
May 30, 2025
Via
Benzinga
Top movers in Friday's session
↗
May 30, 2025
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
Traders are paying attention to the gapping stocks in Friday's session.
↗
May 30, 2025
Traders are paying attention to the gapping stocks in Friday's session. Let's dive into which stocks are experiencing notable gaps.
Via
Chartmill
Synergy CHC Corp. (NASDAQ: SNYR) Taps Beverage Veteran to Drive FOCUSfactor’s Drink Expansion – More Stocks Inside
May 29, 2025
Via
AB Newswire
Topics
Economy
Let's take a look at the stocks that are in motion in today's session.
↗
May 29, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
Alzamend Neuro Stock Rockets On Dosing Of First Human Patient With Lithium-Delivery System AL001 In Phase II Study: Retail’s Thrilled
↗
May 29, 2025
AL001 has the potential to provide the benefits of marketed lithium salts while mitigating currently experienced toxicities associated with lithium.
Via
Stocktwits
Alzamend Neuro (ALZN) Stock Surges On AL001 Phase II Trial Milestone
↗
May 29, 2025
Alzamend Neuro shares surged after dosing the first patient in its AL001 Phase II trial. This novel lithium formulation aims for improved brain delivery and fewer side effects.
Via
Benzinga
Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results
↗
May 29, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
May 29, 2025
Via
Benzinga
Keep an eye on the top gainers and losers in Thursday's session.
↗
May 29, 2025
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
The market is filled with gapping stocks in Thursday's session.
↗
May 29, 2025
Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via
Chartmill
Alzamend Neuro Inc. (NASDAQ: ALZN) Targets Transformative Mental Health Breakthroughs
May 29, 2025
Via
Investor Brand Network
Topics
Artificial Intelligence
Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue
↗
May 29, 2025
Via
Benzinga
BioMedNewsBreaks — Alzamend Neuro, Inc. (NASDAQ: ALZN) Doses First Patient in Phase II Trial for Next-Gen Lithium Therapy AL001
May 29, 2025
Via
Investor Brand Network
What's going on in today's pre-market session
↗
May 29, 2025
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
May 29, 2025
Via
Benzinga
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
May 29, 2025
From
Alzamend Neuro, Inc.
Via
GlobeNewswire
Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
May 19, 2025
From
Alzamend Neuro, Inc.
Via
GlobeNewswire
Which stocks are moving before the opening bell on Tuesday?
↗
May 13, 2025
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Via
Chartmill
Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
May 13, 2025
From
Alzamend Neuro, Inc.
Via
GlobeNewswire
EXCLUSIVE: Alzamend Neuro Initiates First Phase 2 Trial Of Lead Program In Healthy Human Participants
↗
May 13, 2025
Alzamend Neuro starts Phase 2 trial of AL001 with novel coil tech to test improved lithium delivery in the brain for multiple mental health conditions.
Via
Benzinga
Curious about the stocks that are showing activity after the closing bell on Friday?
↗
May 09, 2025
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
Via
Chartmill
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
May 07, 2025
From
Alzamend Neuro, Inc.
Via
GlobeNewswire
EXCLUSIVE: Alzamend Neuro Partners with QMENTA To Advance AI-Powered Imaging For Is Phase 2 Trial Of Lead Program
↗
May 07, 2025
Alzamend Neuro teams up with QMENTA for five AL001 Phase 2 trials at Mass General, targeting Alzheimer's, PTSD, bipolar disorder, and more.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
